路易体痴呆的体液和组织生物标志物：LBDA研讨会报告。

Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.

作者信息

Scott Gregory D, Arnold Moriah R, Beach Thomas G, Gibbons Christopher H, Kanthasamy Anumantha G, Lebovitz Russell M, Lemstra Afina W, Shaw Leslie M, Teunissen Charlotte E, Zetterberg Henrik, Taylor Angela S, Graham Todd C, Boeve Bradley F, Gomperts Stephen N, Graff-Radford Neill R, Moussa Charbel, Poston Kathleen L, Rosenthal Liana S, Sabbagh Marwan N, Walsh Ryan R, Weber Miriam T, Armstrong Melissa J, Bang Jee A, Bozoki Andrea C, Domoto-Reilly Kimiko, Duda John E, Fleisher Jori E, Galasko Douglas R, Galvin James E, Goldman Jennifer G, Holden Samantha K, Honig Lawrence S, Huddleston Daniel E, Leverenz James B, Litvan Irene, Manning Carol A, Marder Karen S, Pantelyat Alexander Y, Pelak Victoria S, Scharre Douglas W, Sha Sharon J, Shill Holly A, Mari Zoltan, Quinn Joseph F, Irwin David J

机构信息

Department of Pathology, Oregon Health and Science University, Portland, OR, United States.

Department of Pathology and Laboratory Services, VA Portland Medical Center, Portland, OR, United States.

出版信息

Front Neurol. 2022 Jan 31;12:805135. doi: 10.3389/fneur.2021.805135. eCollection 2021.

DOI:10.3389/fneur.2021.805135
PMID:35173668
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8841880/
Abstract

The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health, and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology and novel biomarkers were discussed.

摘要

路易体痴呆协会（LBDA）于2021年1月25日举办了一场线上活动——LBDA生物流体/组织生物标志物研讨会，以展示路易体痴呆（LBD，包括路易体痴呆症（DLB）和帕金森病痴呆（PDD））生物标志物的研究进展。会议邀请了来自欧洲和美国的八位国际知名科学家，吸引了来自学术中心、美国国立卫生研究院和制药行业的200多名科学家和医生。会上讨论了确认和量化路易体及阿尔茨海默病病理特征的方法以及新型生物标志物。

相似文献

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]

引用本文的文献

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]

本文引用的文献

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索